Novan, a biotech company focused on dermatology, has recently lowered its IPO to $45 million. Given the difficulty smaller biotechs have encountered this year, Novan should perhaps consider itself lucky that it is even able to go for an IPO. After all, a considerable...

Imagine being handed puzzle to solve that’s made up of literally millions of tiny pieces. Maybe you would sit down and start with the corners, work your way across the edges, and then start piecing together the middle based on like-colors. Now imagine that as...

CRISPR (i.e. clustered regularly interspaced short palindromic repeat), a segment of gene editing treatment that is thought to be one of the cutting edge developments in genetic engineering, is finally approaching clinical trials to be used on humans. Many are hopeful...

MIT Technology Review had some interesting news to break today: the first proposed test of CRISPR gene-editing technology in human beings is being funded by none other than Internet billionaire Sean Parker, the well-known cofounder behind Napster and first president...

After a quarter century of conflict over genetically modified foods, it’s understandable that initial reactions to gene editing—the technical process of editing or removing specific genes of an organism—being applied to produce and livestock have been met with...